- Posted by Saskia Rots
- On 19th August 2021
Stevenage, 6TH July 2021: FourPlus and Cell and Gene Therapy have launched their virtual reality training program for trainee GMP operators at a training day in Stevenage. Training in Good Manufacturing Practice has been developed as part of the Advanced Therapies Apprenticeship Community. The launch day gave staff and trainees and opportunity to try out the program and experience VR, in some cases for the first time.
The training program features a series of fully-immersive interactive modules to prepare staff for the GMP environment, increasing confidence and familiarity with procedures. The modules take place in a realistic virtual facility based on CGT Catapult’s large-scale manufacturing centre in Stevenage and their processes. The training is aligned with the standards of the Manufacturing Technician, Laboratory Technician, Technician Scientist and Modern Apprenticeship programmes.
The launch event began with a walkthrough of the program modules, including: cleanroom orientation, GMP cleaning, cleanroom gowning, and GMP Compliance and Healthy & Safety. See the brochure below for further module details.
This was followed by a product demo and time for each attendee to take the training modules in VR.
FourPlus Co-founders Hayley Mulhall and Ivan Wall say “We are delighted to work with Cell and Gene Therapy Catapult to create a virtual reality training platform for GMP operator trainees. Currently, GMP training requires significant investment of time, infrastructure and equipment that can lead to production downtime. The FourPlus platform will enable training to first be undertaken in virtual reality before the operator sets foot in a GMP facility, which will accelerate the training cycle, increase competence and confidence of operators, and reduce costs associated with production downtime.”
Using cutting-edge VR to deliver GMP training reduces costs and interruptions associated with bringing untrained staff into manufacturing facilities. The time taken for new employees to become operational is reduced, and trainees’ knowledge retention and confidence is improved through the ability to repeat modules at an individual pace.
This innovative training is being delivered by the ATAC, a programme coordinated by CGT Catapult and funded by an £1.5m award from the Industrial Strategy Challenge Fund. The VR courses are now available for industry to license, and for ATAC apprentices and CGT Catapult collaborators to access as part of their training.
For members of wider industry interested in accessing GMP virtual reality training, contact FourPlus by emailing firstname.lastname@example.org to discuss licensing options.
FourPlus are an immersive technology company based in Birmingham, UK. They bring together expertise in life sciences, immersive technology and software engineering to deliver solutions that will accelerate the scale up of modern medicines production. These solutions include virtual reality and digitalisation of traditional training platforms as well as data capture tools for such platforms. Our approach will help to unlock the potential of revolutionary medicines and accelerate their delivery to patients who need them.
For more information, visit www.fourplus.co.uk or contact Dr Hayley Mulhall +44 (0) 7852 113 704 / email@example.com
About Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 350 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK.